View the content of this email online

LOOKING FOR AN EFFICIENT CRISPR DELIVERY SYSTEM ?

Gene editing with LentiFlash
LentiFlash® particles carrying CRISPR-Cas9 technology show promising results to disrupt targeted genes in several therapeutic fields!
Separator

LentiFlash® CRISPR-Cas9 particles allow efficient KO of genes of interest in human primary T cells for multiple applications such as:

 

Cancer immunotherapy approach (discover data on efficient editing of PD1)

 

Antiviral strategies (discover data on efficient editing of CXCR4)

 

All this by guaranteeing a safe and efficient gene transfer even in primary T cells

TO DISCOVER THE DATA GATHERED BY VECTALYS

Click Here
Articles de press

Flash Therapeutics in the press

We are happy to see that the birth of Flash Therapeutics has been largely relayed by the press. In case you missed some of the articles, you can download our Press Book  and take a look at the whole list.

Read more
Image news PR NL

Press release Flash Therapeutics

Vectalys and FlashCell announced that they have merged to create Flash Therapeutics, a new privately held gene therapy company developing gene and cell therapeutics.

Read more

Follow us

Twitter Flash Therapeutics LinkedIn Flash Therapeutics Youtube Flash Therapeutics Google + Flash Therapeutics
www.flashtherapeutics.com
© Flash Therapeutics 2018

Click here to unsuscribe from the mailing list